Four out of six MS drugs recommended by NICE

14 May 2018

The UK National Institute for Health and Care Excellence (NICE) has issued its Final Appraisal Determination (FAD) recommending the use of four out of six disease-modifying therapies in relapsing-remitting multiple sclerosis.

Those recommended for use on the UK’s National Health Service (NHS) are German drugmaker Merck KGaA’s (MRK: DE) Rebif (interferon β-1a), Biogen’s (Nasdaq: BIIB) Avonex (interferon β-1a), Novartis’ (NOVN: VX) Extavia (interferon β-1b) and Teva Pharmaceutical Industries’ (NYSE: TEVA) Copaxone (glatiramer acetate).

These companies must provide the drugs with the discounts agreed in the patient access schemes. In the preliminary guidance from the NICE, issued in December 2017, only the Novartis drug had been recommended for usage, but further negotiations have since taken place, leading to the additional recommendations.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK